• Je něco špatně v tomto záznamu ?

Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension

F. Simko, T. Baka, K. Krajcirovicova, K. Repova, S. Aziriova, S. Zorad, M. Poglitsch, M. Adamcova, RJ. Reiter, L. Paulis,

. 2018 ; 23 (2) : . [pub] 20180129

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033359

The renin-angiotensin-aldosterone system (RAAS) is a dominant player in several cardiovascular pathologies. This study investigated whether alterations induced by l-NAME, (NLG)-nitro-l-arginine methyl ester, a nitric oxide synthase inhibitor, and the protective effect of melatonin are associated with changes in the RAAS. Four groups of 3-month-old male Wistar rats (n = 10) were treated as follows for four weeks: untreated controls, rats treated with melatonin (10 mg/kg/day), rats treated with l-NAME (40 mg/kg/day), and rats treated with l-NAME + melatonin. l-NAME administration led to hypertension and left ventricular (LV) fibrosis in terms of enhancement of soluble, insoluble and total collagen concentration and content. Melatonin reduced systolic blood pressure enhancement and lowered the concentration and content of insoluble and total collagen in the LV. The serum concentration of angiotensin (Ang) 1-8 (Ang II) and its downstream metabolites were reduced in the l-NAME group and remained unaltered by melatonin. The serum aldosterone level and its ratio to Ang II (AA2-ratio) were increased in the l-NAME group without being modified by melatonin. We conclude that l-NAME-hypertension is associated with reduced level of Ang II and its downstream metabolites and increased aldosterone concentration and AA2-ratio. Melatonin exerts its protective effect in l-NAME-induced hypertension without affecting RAAS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033359
003      
CZ-PrNML
005      
20231121102139.0
007      
ta
008      
181008s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules23020265 $2 doi
035    __
$a (PubMed)29382124
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk. 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, 83305 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk.
245    10
$a Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension / $c F. Simko, T. Baka, K. Krajcirovicova, K. Repova, S. Aziriova, S. Zorad, M. Poglitsch, M. Adamcova, RJ. Reiter, L. Paulis,
520    9_
$a The renin-angiotensin-aldosterone system (RAAS) is a dominant player in several cardiovascular pathologies. This study investigated whether alterations induced by l-NAME, (NLG)-nitro-l-arginine methyl ester, a nitric oxide synthase inhibitor, and the protective effect of melatonin are associated with changes in the RAAS. Four groups of 3-month-old male Wistar rats (n = 10) were treated as follows for four weeks: untreated controls, rats treated with melatonin (10 mg/kg/day), rats treated with l-NAME (40 mg/kg/day), and rats treated with l-NAME + melatonin. l-NAME administration led to hypertension and left ventricular (LV) fibrosis in terms of enhancement of soluble, insoluble and total collagen concentration and content. Melatonin reduced systolic blood pressure enhancement and lowered the concentration and content of insoluble and total collagen in the LV. The serum concentration of angiotensin (Ang) 1-8 (Ang II) and its downstream metabolites were reduced in the l-NAME group and remained unaltered by melatonin. The serum aldosterone level and its ratio to Ang II (AA2-ratio) were increased in the l-NAME group without being modified by melatonin. We conclude that l-NAME-hypertension is associated with reduced level of Ang II and its downstream metabolites and increased aldosterone concentration and AA2-ratio. Melatonin exerts its protective effect in l-NAME-induced hypertension without affecting RAAS.
650    _2
$a zvířata $7 D000818
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    12
$a hypertenze $x chemicky indukované $x metabolismus $x patofyziologie $x prevence a kontrola $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melatonin $x farmakologie $7 D008550
650    _2
$a NG-nitroargininmethylester $x škodlivé účinky $x farmakologie $7 D019331
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baka, Tomáš, $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. tomasko.baka@gmail.com. $d 1989- $7 xx0263984
700    1_
$a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. krikratina@gmail.com.
700    1_
$a Repová, Kristína, $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. repova.k@gmail.com. $d 1984- $7 xx0264906
700    1_
$a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. silvia.aziriova@gmail.com.
700    1_
$a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. Stefan.Zorad@savba.sk. $7 xx0310348
700    1_
$a Poglitsch, Marko $u Attoquant Diagnostics, 1030 Vienna, Austria. marko.poglitsch@attoquant.com.
700    1_
$a Adamcova, Michaela $u Department of Physiology, School of Medicine, Charles University, 50003 Hradec Kralove, Czech Republic. adamcova@lfhk.cuni.cz.
700    1_
$a Reiter, Russel J $u Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, TX 78229, USA. reiter@uthscsa.edu.
700    1_
$a Paulis, Ludovit $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. ludovit.paulis@gmail.com. Institute of Normal and Pathological Physiology, Center for Experimental Medicine, Slovak Academy of Sciences, 81371 Bratislava, Slovakia. ludovit.paulis@gmail.com.
773    0_
$w MED00180394 $t Molecules $x 1420-3049 $g Roč. 23, č. 2 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29382124 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20231121102136 $b ABA008
999    __
$a ok $b bmc $g 1340886 $s 1030353
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 23 $c 2 $e 20180129 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace